Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT

Journal of Affective Disorders

Volumn 186, Issue , 2015, Pages 306-311

  Allen, A P ^a,b   Naughton, M ^a   Dowling, J ^a   Walsh, A ^a   Ismail, Muhammad Fahmi ^a   Shorten, G ^a   Scott, L ^a   McLoughlin, D M ^c,d   Cryan, J F ^a,b   Dinan, T G ^a,b   Clarke, G ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c St Patrick's University Hospital   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Biomarker; Brain derived neurotrophic factor; ECT; Ketamine; Treatment resistant depression

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; KETAMINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BIOMARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROCONVULSIVE THERAPY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938935980     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2015.06.033     Document Type: Article

References (44)

1. M. aan het Rot, K.A. Collins, J.W. Murrough, A.M. Perez, D.L. Reich, D.S. Charney, and S.J. Mathew Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression Biol. Psychiatry 67 2010 139 145
2. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biolog. Psychiatry 47 2000 351 354
3. L. Bocchio-Chiavetto, R. Zanardini, M. Bortolomasi, M. Abate, M. Segala, M. Giacopuzzi, M.A. Riva, E. Marchina, P. Pasqualetti, J. Perez, and M. Gennarelli Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients Eur. Neuropsychopharmacol. 16 2006 620 624
4. A.R. Brunoni, C. Baeken, R. Machado-Vieira, W.F. Gattaz, and M. Vanderhasselt BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis World J. Biol. Psychiatry 15 2014 411 418
5. A.R. Brunoni, M. Lopes, and F. Fregni A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression Int. J. Neuropsychopharmacol. 11 2008 1169 1180
6. J. Bumb, S. Aksay, C. Janke, L. Kranaster, O. Geisel, P. Gass, R. Hellweg, and A. Sartorius Focus on ECT seizure quality: serum BDNF as a peripheral biomarker in depressed patients Eur. Arch. Psychiatry Clin. Neurosci. 265 2014 1 6
7. P. Campion Comparison of ketamine vs. ECT in major depressive disorder: need for ECT standard dosing and duration parameters Psychiatry Res. 225 2015 216
8. B. Chen, D. Dowlatshahi, G.M. MacQueen, J. Wang, and L.T. Young Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication Biol. Psychiatry 50 2001 260 265
9. A. Clark-Raymond, and A. Halaris VEGF and depression: a comprehensive assessment of clinical data J. Psychiatr. Res. 47 2013 1080 1087
10. R.S. Duman, G.R. Heninger, and E.J. Nestler A molecular and cellular theory of depression Arch. Gen. Psychiatry 54 1997 597 606
11. W.C.J. Duncan, S. Sarasso, F. Ferrarelli, J. Selter, B.A. Riedner, N.S. Hejazi, P. Yuan, N. Brutsche, H.K. Manji, G. Tononi, and C.A.J. Zarate Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder Int. J. Neuropsychopharmacol. 16 2013 301 311
12. B. Fernandes, C.S. Gama, R. Massuda, M. Torres, D. Camargo, M. Kunz, P.S. Belmonte-de-Abreu, F. Kapczinski, M.P. de Almeida Fleck, and M. Inês Lobato Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients Neurosci. Lett. 453 2009 195 198
13. A.J. Ferrari, F.J. Charlson, R.E. Norman, S.B. Patten, G. Freedman, C.J. Murray, T. Vos, and H.A. Whiteford Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010 PLoS Med. 10 2013 e1001547
14. H.W. Folkerts, N. Michael, R. Tölle, K. Schonauer, S. Mücke, and H. Schulze-Mönking Electroconvulsive therapy vs. paroxetine in treatment-resistant depression - a randomized study Acta Psychiatr. Scand. 96 1997 334 342
15. M. Ghasemi, M.H. Kazemi, A. Yoosefi, A. Ghasemi, P. Paragomi, H. Amini, and M.H. Afzali Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder Psychiatry Res. 215 2014 355 361
16. C.N. Haile, J.W. Murrough, D.V. Iosifescu, L.C. Chang, R.K. Al Jurdi, A. Foulkes, S. Iqbal, J.J.I. Mahoney, R.I. De La Garza, D.S. Charney, T.F. Newton, and S.J. Mathew Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression Int. J. Neuropsychopharmacol. 17 2014 331 336
17. F. Karege, G. Vaudan, M. Schwald, N. Perroud, and R. La Harpe Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs Mol. Brain Res. 136 2005 29 37
18. J. Kornhuber, and M. Weller Patient selection and remission rates with the current practice of electroconvulsive therapy in Germany J. ECT 11 1995 104 109
19. A.E. Lepack, M. Fuchikami, J.M. Dwyer, M. Banasr, and R.S. Duman BDNF release is required for the behavioral actions of ketamine Int. J. Neuropsychopharmacol. 18 2015
20. M. Lommatzsch, D. Quarcoo, O. Schulte-Herbrüggen, H. Weber, J.C. Virchow, H. Renz, and A. Braun Neurotrophins in murine viscera: a dynamic pattern from birth to adulthood Int. J. Dev. Neurosci. 23 2005 495 500
21. A. Minelli, R. Zanardini, M. Abate, M. Bortolomasi, M. Gennarelli, and L. Bocchio-Chiavetto Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35 2011 1322 1325
22. M.L. Molendijk, B.A.A. Bus, P. Spinhoven, B.W.J.H. Penninx, G. Kenis, J. Prickaerts, R.C.O. Voshaar, and B.M. Elzinga Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment Mol. Psychiatry 16 2011 1088 1095
23. M.L. Molendijk, P. Spinhoven, M. Polak, B.A.A. Bus, B.W.J.H. Penninx, and B.M. Elzinga Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484) Mol. Psychiatry 19 2014 791 800
24. M. Naughton, G. Clarke, O.F. O'Leary, J.F. Cryan, and T.G. Dinan A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action J. Affect. Disord. 156 2014 24 35
25. W.A. Nockher, and H. Renz Neurotrophins in clinical diagnostics: pathophysiology and laboratory investigation Clin. Chim. Acta 352 2005 49 74
26. R.M. O'Connor, S. Grenham, T.G. Dinan, and J.F. Cryan microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus Int. J. Neuropsychopharmacol. 16 2013 1885 1892
27. O.F. O'Leary, T.G. Dinan, and J.F. Cryan Faster, better, stronger: towards new antidepressant therapeutic strategies Eur. J. Pharmacol. 753 2015 32 50
28. W. Pan, W.A. Banks, M.B. Fasold, J. Bluth, and A.J. Kastin Transport of brain-derived neurotrophic factor across the blood-brain barrier Neuropharmacology 37 1998 1553 1561
29. A. Pillai, A. Kale, S. Joshi, N. Naphade, M. Raju, H. Nasrallah, and S.P. Mahadik Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology Int. J. Neuropsychopharmacol. 13 2010 535 539
30. M. Polyakova, K. Stuke, K. Schuemberg, K. Mueller, P. Schoenknecht, and M.L. Schroeter BDNF as a biomarker for successful treatment of mood disorders: A systematic & quantitative meta-analysis J. Affect. Disord. 174 2015 432 440
31. J. Prudic, R.F. Haskett, B. Mulsant, K.M. Malone, H.M. Pettinati, and S. Stephens Resistance to antidepressant medications and short-term clinical response to ECT Am. J. Psychiatry 153 1996 985 992
32. J. Prudic, H.A. Sackeim, and D.P. Devanand Medication resistance and clinical response to electroconvulsive therapy Psychiatry Res. 31 1990 287 296
33. C. Rapinesi, G.D. Kotzalidis, M. Curto, D. Serata, V.R. Ferri, P. Scatena, P. Carbonetti, F. Napoletano, J. Miele, S. Scaccianoce, A. Del Casale, F. Nicoletti, G. Angeletti, and P. Girardi Electroconvulsive therapy improves clinical manifestations of treatment-resistant depression without changing serum BDNF levels Psychiatry Res. 227 2015 171 178
34. H.A. Sackeim, R.F. Haskett, B.H. Mulsant, and et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial JAMA 285 2001 1299 1307
35. H.A. Sackeim, J. Prudic, D.P. Devanand, P. Decina, B. Kerr, and S. Malitz The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression J. Clin. Psychopharmacol. 10 1990 96 104
36. I. Salehi, S.M. Hosseini, M. Haghighi, L. Jahangard, H. Bajoghli, M. Gerber, U. Pühse, R. Kirov, E. Holsboer-Trachsler, and S. Brand Electroconvulsive therapy and aerobic exercise training increased BDNF and ameliorated depressive symptoms in patients suffering from treatment-resistant major depressive disorder J. Psychiatr. Res. 57 2014 117 124
37. S. Sen, R. Duman, and G. Sanacora Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications Biol. Psychiatry 64 2008 527 532
38. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G.C. Dunbar The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic interview for DSM-IV and ICD-10 J. Clin. Psychiatry 59 1998 22 33
39. D. Sisti, A.G. Segal, and M.E. Thase Proceed with caution: Off-label ketamine treatment for major depressive disorder Curr. Psychiatry Rep. 16 2014 1 5
40. S.M. Taylor Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive therapy J. ECT 24 2008 160 165
41. A.L. Teixeira, I.G. Barbosa, B.S. Diniz, and A. Kummer Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function Biomark. Med. 4 2010 871 887
42. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, A.A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R.H. Howland, B. Lebowitz, P.J. McGrath, K. Shores-Wilson, M. Biggs, M.M. Balasubramani, G.K. Fava, and M. Team, S.D.S. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice Am. J. Psychiatry 163 2006 28 40
43. UK ECT Review Group Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis Lancet 361 2003 799 808
44. C.A. Zarate, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an n-methyl-D-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 2006 856 864